Accelovance Leadership

Accelovance's commitment to providing quality services starts with our people. Our team members are passionate about their work and are dedicated to fulfilling each client's requirements in a timely, accurate, well managed and cost-effective manner.

Our executive management team combines entrepreneurial business talents, clinical and medical expertise, and biotech industry experience to effectively lead the vision of the company. The following individuals are the foundation of Accelovance's ability to the address clinical needs and business objectives of those we serve.

Stephen J. Trevisan, President and CEO, Accelovance

Steve Trevisan

Mr. Trevisan is an entrepreneur who has founded four companies, including Accelovance, Inc. in 2005. Prior to Accelovance, Mr. Trevisan founded TherImmune Research Corporation, a Contract Research Organization (CRO) specializing in preclinical and early stage clinical drug development services for the pharmaceutical, biotechnology, and government markets. He also founded CommSys Corporation, a provider of outsourced billing services to the telecommunications industry. In 1987, Mr. Trevisan co-founded his first company, National Clinical Research Centers (NCRC), a CRO specializing in Phase II-IV clinical studies. NCRC deployed a unique method for running clinical trials which was successful in reducing the timeframe in conducting multi-center trials in broad-based indications. Each of Mr. Trevisan's prior companies maintained year-over-year growth and were ultimately acquired by public companies.

Vita Lanoce, MS, Chief Operating Officer

Vita Lanoce, MS

Ms. Lanoce leads the Global Clinical Operations organization. Ms. Lanoce ensures operational excellence is achieved by applying high industry standards, policies, systems and processes across the organization. In addition to leading Clinical Operations, Ms. Lanoce oversees the organization’s Biometrics division, including Data Management and Biostatistics. Ms. Lanoce has more than 22 years of experience in the clinical research industry. Prior to joining Accelovance, Ms. Lanoce had a 15 year tenure with Radiant Development where she held positions of increasing responsibility including Site Director, Director Regional Operations, Director Operations, and Vice President Clinical Operations. Prior to joining Radiant Development, Ms. Lanoce was the Managing Partner and Director of Clinical Operations for two clinical research facilities located in Stuart and Lake Worth, Florida. Ms. Lanoce has held a variety of positions in the biopharmaceutical industry including Clinical Scientist at Bristol-Meyers Squibb and Regional Manager for Covance. Ms. Lanoce holds a Master's of Science in Biomedical Engineering from Rutgers University and a Bachelor of Arts in Biology from Manhattanville College.

 

 

Jeffrey T. Rudolph, MBA, Chief Commercial Officer

Jeff Rudolph

Jeffrey T.  Rudolph, MBA has 25 years of CRO and pharma/biotech industry experience including extensive global CRO team leadership experience. Jeff is a seasoned planner and CRO business executive who knows how to deliver results in a "scale up" environment. During his time in the industry, he has worked with clients ranging from small biotech to large pharma, providing solutions that address their specific needs. In his role as vice president, Global Business Development at Chiltern, Jeff was responsible for managing the global biotech sales team in North America, Europe and Asia Pacific. Prior to Chiltern, Jeff spent four years as one of five regional business development Executive Directors for ICON, and four years each in business development at PRA Health Sciences and SGS Life Sciences. Additionally, Jeff spent four years as Global VP of Sales/Marketing for Healthcare Communications Group, and was employee number five when this organization was a startup (the company eventually sold after significant growth/expansion). His background encompasses extensive professional business experience growing pharma services companies from scratch to $100M/year in revenue. He holds a Master of Business Administration degree from the University of Texas and a B.S. in Biochemistry from the University of Missouri.

Harish Dave, MD, Chief Medical Officer

Harish Dave, MD

Dr. Dave leads Accelovance's Medical Affairs & Drug Safety group. Dr. Dave has 25+ years of Phase I-IV clinical research experience including the conduct of over a 100 studies with a focus on hematology, oncology and transplantation as well as other areas of internal medicine. Dr. Dave provides integrated drug development and therapeutic advice, management of clinical trials, and expertise and due diligence for biotech, small, medium and large pharma and VC companies. He has basic science expertise in gene regulation, gene therapy and tumor immunology, clinical and academic expertise in hematology including coagulation disorders, oncology and transplantation, and industry experience in hematology/oncology drug development from pre-clinical to phase IV space and in biosimilars/biobetters and immunotherapeutics. Prior to joining Accelovance, Dr. Dave held positions at Quintiles, George Washington University Medical Center and VA Medical Center in Washington, DC and NIH in Bethesda, MD. Dr. Dave holds a MB, ChB from the University of Sheffield and a MBA from the TRIUM program (jointly awarded by NYU, London School of Economics and HEC).

Jamie Oliver, PharmD, Chief Science Officer

Jamie Oliver

Dr. Oliver serves as our Chief Science Officer, leveraging his strategic, scientific, and industry experience to guide Sponsor product development. Prior to joining the Accelovance team in 2013, Dr. Oliver was the Chief Executive Officer at Phage Pharmaceuticals, Inc. and prior to that was a Principal at Trinity Drug Partners, LLC. Dr. Oliver has amassed significant clinical research experience in both preclinical and clinical experimentation in academia and the pharmaceutical industry. Dr Oliver has strong therapeutic experience in the areas of oncology, hematology, vaccines, nutritional support, cytokines regulation, infectious diseases, immunopharmacology, renal disease, and transplantation. Dr. Oliver has served on the executive management team of both public and private pharmaceutical companies in a Vice President/COO role. He has served on the clinical faculty of Mercer University, Emory University, and the University of North Carolina. He also was a collaborative researcher with the Centers for Disease Control and Prevention, Hospital Infections Division. Dr. Oliver received his Doctor of Pharmacy degree from Mercer University in Atlanta. He has published a number of peer-reviewed articles in the area of immunopharmacology and oncology and is a member of the American Society of Clinical Oncology.

Jamie Chorlton, SVP, Clinical Operations Europe

Jamie Chorlton

Jamie Chorlton is the Senior Vice President, Clinical Operations Europe. Jamie was a cofounder and Chief Executive Officer at Altair Clinical, Ltd., prior to its acquisition by Accelovance in January, 2015. Before launching Altair Clinical, Jamie served as Chief Operating Officer at Venn Life Sciences, Ltd. Jamie has also held senior managerial roles at Novella Clinical, Ltd., and previously Matrix Contract Research Ltd., where he played an instrumental role in the growth of both organizations. In addition to a decade in the CRO industry, Jamie has also served in operational roles in the biotech and pharma industries, working at Oxxon Therapeutics and Wyeth Research respectively. Jamie has a Bachelor of Science degree in Biomedical Technology from Sheffield Hallam University.

Wendy Wang MD, PhD, Managing Director Accelovance China

Wendy Wang MD

Dr. Wendy (Wen-Ying) Wang is the Managing Director at Accelovance China. As Head of Accelovance China, Dr. Wang helps western pharmaceutical companies with global clinical trial registration, import drug registration, regulatory consultancy, clinical site management, and project management of multi-center global clinical trials in China. Dr. Wang has broad experiences in research, technical, sales, quality, medical and regulatory affairs within the biotechnology and pharmaceutical industries in the areas of bioactive enzymes, medicines, and vaccines in Greater China and Asia Pacific regions. Dr. Wang earned her clinical medicine degree from Shandong Weifang Medical College, Master's degree in gastroenterological physiology from Peking Union Medical College, and her PhD in the regulation of angiogenesis by vascular endothelial growth factor from the University of Bristol in the United Kingdom.

Jeff Levin, Vice President, Human Resources

Jeff Levin

Mr. Levin is the Vice President of Human Resources and is responsible for providing leadership in the development, communication, and execution of a human resource strategies in support of organizational goals. Among his many areas of focus, Mr. Levin leads initiatives for talent management, compensation, and employee and leadership development. He also directs the day-to-day administration of benefits and employee relations. Mr. Levin has more than 15 years’ experience as a human resources professional in the life sciences sector. Prior to joining Accelovance, Mr. Levin was with Cardiocore for seven years and Medimmune for seven years as a Director of Human Resources. Mr. Levin holds a BS degree from the University of Maryland.

Mary Lyda, Vice President, Global Quality Assurance

Mary Lyda

Ms. Lyda provides strategy and direction to assure compliance with global GCP Regulations and Guidelines, and drives corporate initiatives for the harmonization of policies, procedures and training. Ms. Lyda has over 35 years’ experience in the oversight of preclinical and clinical research. She started her career at the FDA performing a variety of roles for 22 years in the enforcement of regulations and harmonization initiatives with international regulatory agencies to establish a framework for GCPs. She brings global experience to Accelovance having lived and worked in Switzerland for 10 years in the pharma industry. Ms. Lyda was a Consultant with PAREXEL International before joining Novartis Pharma Quality Assurance in Basel, in 2004. She returned to the US in 2008 and served 8 years at Worldwide Clinical Trials and was instrumental in harmonization of five companies as the Vice President Global QA before joining Accelovance.